Skip to main content

Table 2 Cox proportional hazard analyses on DFS in patients with CRC

From: Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer

Variables DFS in the patients with I–IV stage CRC DFS in the patients with I–III stage CRC
Univariate Multivariate Univariate Multivariate
P value HR [95% CI] P value HR [95% CI] P value HR [95% CI] P value HR[95%CI]
NTRK3 hypermethylation 0.014 2.194 (1.169, 4.117) 0.004 2.688 (1.355, 5.333) 0.004 2.565 (1.354, 4.857) 0.015 2.630 (1.206, 5.734)
Older age 0.011 1.952 (1.168, 3.263) 0.060 1.723 (0.977, 3.038) 0.002 2.401 (1.364, 4.227) 0.010 2.334 (1.217, 4.477)
Male (vs. female) 0.574 1.153 (0.702, 1.894)    0.484 1.207 (0.713, 2.043)   
Rectal tumor (vs. colon tumor) 0.479 1.192 (0.733, 1.939)    0.341 1.087 (0.915, 1.291)   
Tumor size ≥ 4.5 0.056 1.655 (0.988, 2.772)    0.081 1.624 (0.943, 2.799)   
Poor differentiation 0.581 1.193 (0.637, 2.233)    0.553 1.220 (0.633, 2.353)   
Lymphovascular invasion 0.052 2.087 (0.995, 4.378)    0.022 2.387 (1.131, 5.038) 0.003 3.287 (1.465, 7.373)
Perineural invasion 0.350 1.455 (0.663, 3.195)    0.158 1.770(0.801, 3.912)   
Advanced TNM stage 0.003 2.125 (1.300, 3.473) < 0.001 2.704 (1.528, 4.790) 0.019 1.854 (1.107, 3.103) 0.039 1.978 (1.034, 3.784)
CIMP positive status 0.265 1.935 (0.607, 6.169)    0.186 2.191 (0.685, 7.010)   
MSI 0.316 1.350 (0.751, 2.427)    0.138 1.599(0.860, 2.973)   
KRAS mutation 0.113 1.566 (0.899, 2.726)    0.067 1.743 (0.962, 3.157)   
BRAF mutation 0.010 3.376 (1.338, 8.519) 0.049 2.563 (1.004, 6.551) 0.003 4.122 (1.621, 10.485) 0.595 1.443 (0.373, 5.591)
Ki-67 > 25% 0.458 0.806 (0.456, 1.425)    0.675 0.877 (0.476, 1.617)   
CA19-9 > 37 0.078 1.780 (0.938, 3.377)    0.191 1.589 (0.794, 3.179)   
CEA > 5 0.095 1.591 (0.923, 2.741)    0.048 1.769 (1.005, 3.111) 0.772 1.122 (0.514, 2.447)
  1. NTRK3: neurotropic tropomyosin receptor kinase 3; CIMP: CpG island methylator phenotype; MSI: microsatellite instability; KRAS: kirsten rat sarcoma viral oncogene; BRAF: B-Raf proto-oncogene, serine/threonine kinase; Ki-67: kiel67 antigen; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen